Paper Details

  1. Home
  2. Paper Details

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

Author: BaronB, BoogerdW, Bravo MarquesJ, ChinotO, De BeuleN, KrosJ M, TaphoornM J B, VechtC J, van den BentM J, van der RijtC C D

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Temozolomide (TMZ) was investigated in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after prior PCV chemotherapy and radiation therapy.
Paper Details　
Original Abstract of the Article :
Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine. Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma. We inv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12649108

データ提供：米国国立医学図書館（NLM）

A New Hope for Oligodendroglioma Treatment

Oligodendroglioma is a type of brain tumor that can be challenging to treat. This study, published in the journal [Journal Name], investigates the effectiveness of temozolomide (TMZ) as a second-line chemotherapy for recurrent oligodendroglioma after prior PCV (procarbazine, lomustine, and vincristine) chemotherapy.

The study explores the potential of TMZ, a new alkylating and methylating agent, as a treatment option for recurrent oligodendroglioma. The study found that TMZ showed high response rates in patients with recurrent oligodendroglioma and mixed oligoastrocytomas after prior PCV chemotherapy and radiation therapy. These findings suggest that TMZ could be a valuable treatment option for patients with recurrent oligodendroglioma who have received prior PCV chemotherapy.

TMZ: A Promising Second-Line Treatment for Oligodendroglioma

This study provides encouraging results for patients with recurrent oligodendroglioma, suggesting that TMZ could be an effective second-line chemotherapy option. Its high response rates in patients who have received prior PCV chemotherapy offer a glimmer of hope for improved treatment outcomes.

Navigating Brain Tumor Treatment: Hope and Resilience

This study highlights the importance of exploring new treatment options for brain tumors, particularly those that have recurred. The effectiveness of TMZ offers hope for patients with recurrent oligodendroglioma, providing a new avenue for treatment and potentially extending their lives. It’s a reminder that even in the seemingly endless expanse of medical research, breakthroughs can emerge, bringing hope and healing to those who need it most.

Dr.Camel's Conclusion

TMZ shows promise as a second-line chemotherapy option for recurrent oligodendroglioma, offering a potential new avenue for treatment and improved outcomes for patients with this challenging condition. It’s a reminder that even in the seemingly endless expanse of medical research, breakthroughs can emerge, bringing hope and healing to those who need it most.

Date :
  1. Date Completed 2003-07-22
  2. Date Revised 2020-02-03
Further Info :

Pubmed ID

12649108

DOI: Digital Object Identifier

S0923-7534(19)64093-7

Related Literature

Article Analysis
・Side Effects of lomustine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.